Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS3219533 A
Tipo de publicaciónConcesión
Fecha de publicación23 Nov 1965
Fecha de presentación29 Nov 1962
Fecha de prioridad29 Nov 1962
También publicado comoDE1492015A1
Número de publicaciónUS 3219533 A, US 3219533A, US-A-3219533, US3219533 A, US3219533A
InventoresMullins John D
Cesionario originalMerck & Co Inc
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
US 3219533 A
Resumen  disponible en
Imágenes(5)
Previous page
Next page
Reclamaciones  disponible en
Descripción  (El texto procesado por OCR puede contener errores)

United States Patent AEROSOL SOLID MEDICAMENT IN PROPELLANT AND LOW-LEVEL ETHANOL AVOIDING HIGH- ER-LEVEL ETHANOL DISPERSED-SOLID RE- FLOCCULATIGN John D. Mullins, Evansville, Ind., assignor to Mierck & Co., Inc., Railway, N.J., a corporation of New Jersey No Drawing. Filed N 0v. 29, 1962, Ser. No. 241,022

8 Claims. (Cl. 167-82) This invention relates to pharmaceutical compositions and more particularly to self-propelling medicament compositions and the method of treatment therewith. This application is a continuation-in-part of my application Serial No. 147,444, filed October 25, 1961, which in turn is a continuation-in-part of Serial No. 112,799, filed May 26, 1961, both now abandoned.

The administration of medicaments by inhalation has been known and employed with varying degrees of success for many years. Usually aqueous solutions of the medi cament were atomized by mechanical means and inhaled. Inhalation of medicated steam vapors has been employed. Insufilation of fine powders, again with the aid of mechanical devices, also has been practiced. However, in general, those devices which were eiiective in reducing the particles of medicament to a size compatible with entry into the bronchial tree were large, cumbersome and could not be employed outside of the home, clinic or hospital. Many of the smaller, portable devices were inefiicient or totally ineffective.

The introduction of nebulizers with rubber airbulbs to aspirate the medicament in the lung cavity represented a notable advance in more or less portable devices but their utility was limited because of great variations in pressure obtained depending upon how the device was used. A still further advance was the development of self-propelling medicament compositions such as described in United States Patent No. 2,868,691. Unfortunately, the compositions described therein are not as satisfactory as is desired for inhalation therapy because such compositions do not provide sufiicient deposition and retention of the medicated particles where needed to obtain maximum therapeutic eilect, namely, on the mucous memberanes of the bronchial tree.

As a result of the aforementioned problems, therapy by inhalation has gone through various cycles of use and disuse and today is not widely practiced. Yet in many conditions, particularly those which involve the respiratory tree, as in asthma, bronchitis, infectious and inflammatory diseases of the respiratory tract, and even coughing and the allergic manifestations of the common cold, proper inhalation therapy woud be exceedingly useful.

According to the present invention, there are now provided stable self-propelling medicated compositions which have the properties and characteristics which render them highly useful for both inhalation and ophthalmic therapy. The self-propelling compositions of this invention are substantially anhydrous suspensions or dispersions comprised essentially of a solid medicament uniformly dispersed or suspended throughout a substantially anhydrous liquid carrier comprised essentially of a non-toxic propellant and ethanol. These compositions, when prepared cmploying the above components, described more fully hereinafter, provide an excellent means for administering medicaments in aerosol form for inhalation and ophthalmic therapy. For example, it has been found that when the compositions of this invention are utilized for inhalation therapy there is obtained greater deposition and retention of the medicated particles in that region of the bronchial tree where it is optimally utilized. As a result of such efficient aerosolization of the medication upon target lung tissue, it is possible in many cases to significantly reduce the dose of the medication employed whereby, with some drugs, such as the anti-inflammatory steroids, 8. direct benefit accrues to the patient in the elimination of some of the classic side eilects of the drug encountered when they are administered over a prolonged period of time by mouth or by parenteral injection.

In addition to the above, it has also been found that by virtue of the etficient aerosolization of the medicament upon the lung tissue, the absorption of many medicaments into the blood stream is greatly enhanced. Accordingly, the compositions of the present invention are also particularly useful for the systemic treatment of various diseases of the body which have heretofore been treated by parenteral administration of antibiotics and other medicaments such as insulin, adrenaline and triodothyronine. Thus, for example, employing insulin as the medicament, diabetes and other diseases which respond to insulin therapy, may be treated by inhalation therapy utilizing the compositions of this invention. The treatment of such diseases by inhalation therapy obviates the need for administering the medicament via the parenteral route which is often discomforting to the patient. Furthermore, the treatment of such diseases by inhalation therapy utilizing the compositions of this invention minimizes or eliminates certain of the classic side effects associated with parenteral administration, particularly intravenous injection.

The self-propelled compositions of the present invention are also particularly useful for ophthalmic therapy. At present, medicaments are normally applied to the eye either in the form of aqueous suspensions or solutions or as ointments. In the former, the medicament is applied by dropper or eye cup whereas with the latter, application is made by pressing a small amount of ointment from a tube around the area of the eyelid which is then mechanically spread by movement of the eye itself. Both methods, however, present considerable problems, especially for self-medication. Thus, for example, accurate positioning is diflicult and the application is often wasteful and unsightly. Furthemore, utilizing these methods and compositions, the drug is administered to the eye by direct impact which may give rise to irritation. The self-propelling medicament compositions of this invention, on the other hand, can be self-applied more readily with appreciably less waste of the drug and without leaving any unsightly appearance as is the case with ophthalmic ointments. In addition, the self-propelled compositions of the present invention provide for the administration of the drug to the eye as a fine mist, thereby substantially eliminating the irritation and waste often resulting when the drug is administered by conventional means.

The liquid carrier employed in the novel compositions of this invention is com-prised essentially of a mixture of a non-toxic liquid propellant and ethanol. The propellant, which constitutes the major portion of the carrier, should be non-toxic, have a vapor pressure between about 15 and pounds, and preferably between about 35 and 40 pounds per square inch gauge at 70 F., and be completely miscible with ethanol. Among the propellants having the above characteristics are the fluorinated or fluorochlorinated lower saturated aliphatic hydrocarbons. The preferred propellants of this type are the halogenated alkanes containing not more than two carbon atoms and at least one fluorine atoms. Illustrative of these are trichloromonofluoromethane, dichlorodifluoromethane, monochlorotrifluoromethane, dichloromonofluoromethane and 1,2-dichloro-1,1,2,2-tetrafiuoroethane. These compounds are available commercially from E. I. du Pont de Nemours and Company under the trade name Freon.

It will be realized that the fluorinated or fluorochlorinated lower saturatedaliphatic hydrocarbons having the above-mentioned characteristics may be employed singu In addition, it will be larly or in compatible admixtures. further realized that other non-toxic propellants having a vapor pressure without the limits prescribed above may be utilized in compatible admixtures with or Without one or more propellants having the required vapor pressure providing that the vapor pressure of such mixtures is within the prescribed range.

The. presence of ethanol as a constituent of the liquid carrier is critically essential for the preparation of satisfactory self-propelling medicated compositions contemplated by the present invention. The ethanol, while also serving as additional diluent for the suspended medicated particles, is absolutely essential to prevent agglomeration or settling out of the medicated particles. The discovery that ethanol can be utilized for the prevention of agglomeration or settling out of the medicated particles permits the preparation of stable self-propelling medicated compositions without the necessity of employing other agents, such as surfactants, for this purpose. This represents a decided advancement of the art since it is now possible, for the first time, to prepare stable self-propelling compositions which upon ejection and inhalation thereof permits essentially only the medicament to enter the bronchial tree. This stems from the fact that during the ejectioninhalation cycle, the propellant and ethanol are so rapidly volatilized that very little, if any, enters the bronchial tree. This represents a decided advantage over inhalation compositions containing other agents to prevent agglomeration which, because of their physical properties necessarily reach the desired site of deposition together with the medicament.

The medicaments employed in the compositions of this invention should, of course, -be therapeutically suitable for inhalation or ophthalmic therapy as the case may be. In addition, it is critical in order to formulate the compositions of the present invention, that the medicament be a solid at ordinary room temperature, substantially anhydrous in form and virtually insoluble in' the liquid carrier employed. Furthermore, it is also critical that the medicament have a particle size of at least about 0.5 to- 1 micron and no greater than about microns. Pref erably, the particle size of the-medicament is such that 95%- by' weight of the particles are in the range of from about 0.5 to about 4 microns. With these critical requirements in mind, medicaments which can be satisfactorily employed in the self-propelled inhalation and/or ophthalmic compositions of this invention include insulin, triodo'thyronine and adrenaline; the anti-inflammatory steroids such as hydrocortisone, prednisolone and dexamethasone; antibiotics such as penicillin, neomycin, polymixin, tetracycline, chlortetracycline and oxytetracycline; broncho-dilators such as isoproterenol, phenisonone, epinephrine, phenylephri-ne and metaraminol; anti-nauseants such as cyclizine, meclizine, pipamazine, dimenhydrinate, trimethobenzamide; analgesics such as ergotamine; antihistamines such as cyproheptadine; antitussives such as noscapine, and mixtures thereof. These medicaments may be employed in their free form or suitable derivatives such as estes, salts and the like may be utilized. It will, of course, be appreciated by those in the art that the selection of the particular form of the medicament employed will be dependent upon itssolubility characteristics in the particular carrier system utilized. In addition, it is preferred, but not essential, that the medicament utilized in the preparations intended for inhalation therapy also be water-soluble and for this purpose the form of medicament can be selected accordingly.

It is important that the amount of ethanol employed in the compositions of the present invention be kept at a minimum. Preferably, it should not exceed 5% by Weight of the final formulation because higher levels of ethanol may adversely affect the dispersion in that it may cause some reflocculation of the dispersed solids. Desirably, the ethanol is present in an amount of from about 0.5 to about 5.0% and preferably 1.5 to 3.0% by weight of the formulation. In those compositions intended for ophthalmic use, the amount of ethanol preferably should not exceed 3.0%. The concentration of medicament in the self-propelled compositions of the present invention will, of course, vary depending on the medicament and carrier employed as Well as the treatment desired. However, in general, the amount of medicament should generally constitute from about 0.02% to about 5% and preferably from about 0.05% to about 1% by weight of the composition, with the propellant constituting the remainder of the composition.

In preparing the compositions of this invention, the medicament is first ground, milled or micronized to a particle size in the range specified hereina-bove and then dried by conventional methods to substantially remove any water which may be present. A desired amount of finely divided and substantially anhydrous medicament is then suspended in a measured amount of carrier which has previously been cooled to a temperature of about 25 F. ina suitable container. Without permitting the temperature of the suspension to rise above the boiling point of the propellant, the container which may be metal, glass or plastic is sealed with a closure equipped with a suitable dispensing valve arrangement. The quantities of the components introduced into the container are calculated to provide the desired concentration in the final composition. Upon Warming to room temperature, the contents of the container are mixed by agitation of the container.

An alternative and preferred procedure for preparing the compositions of the invention comprises milling a suitable quantity of medicament, which has previously been dried to remove substantially all water, in ethanol, to form a suspension concentrate containing the medicament having the required particle size; subdividing and diluting the thus obtained concentrate in a suitable container with sufiicient propellant, previously cooled to about 25 F., to provide the desired concentration of the medicament and ethanol in the final formulation and, Without allowing the temperature of the formulation to rise above the boiling point of the propellant, sealing the container with a closure equipped with a suitable dispensing valve arrangement which is preferably metered to dispense an effective dose of the medicament per application or over several applications during a single day. A suitable metered dispensing valve for this purpose is described in United States Patent No. [2,721,010.

Since, in all ophthalmic formulations, sterility must be assured, this factor must be considered. The medicament considered for use in such preparations can be sterilized using ethylene oxide treatment in the conventional manner. The propellant, While not particularly susceptible to bacterial invasion, may, nevertheless, be sterilized by filtration. The containers, previously sterilized by usual procedures, are filled in a sterile area. Once filling is complete, sterility need not be a factor since the pressurized container is never opened.

The following examples illustrate the preparation of specific compositions provided by this invention but it is understood that the invention is not to be restricted thereby to the embodiments described in these examples.

,5. Example 1 A self-propelling medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:

Percent by weight 13.5 grams of substantially dry dexamethasone phosphate and 5.35 grams of substantially dry isoproterenol sulfate are milled in 75 grams of absolute ethanol to a particle size in the range of from about 0.5 to microns. The resulting suspension concentrate is then subdivided into 500 portions in suitable aerosol containers and each diluted with 14.81 grams of a propellant mixture, previously cooled to about 25 F., containing 35% Freon 12 and 65% Freon 114. Without permitting the temperature of the resulting formulations (which contain grams of material) to rise above the boiling point of the propellant component, the metal containers are then sealed with a closure equipped with a metered valve capable of dispensing the desired amount of medicament per application. Using a metered 70 mg. valve, there will be provided 0.126 mg. of the steroid and 0.049 mg. of the isoproterenol sulfate per application. A regimen of 3 applications four times a day of the formulation is suitable for inhalation therapy.

Example 2 A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:

Weight, g.

Dexamethasone phosphate, disodium 0.027

Ethanol (absolute) 0.150

Dichlorodifiuoromethane (Freon 12) 5.188 1,2-dichloro-1, 1,2,2-tetrafluoroethane (Freon 114) 9.635

Example 3v A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:

Weight, g. Dexamethasone phosphate, disodium 0.027 Isoproterenol sulfate 0.011 Ethanol (absolute) 0.300 Dichlorodifiuoromethane (Freon 12) 5.132 1,2-dichloro-l,1,2,2-tetrafluoroethane (Freon 114) 9.530

The medicaments, previously dried to remove substantially all water, are milled in ethanol to a particle size in the range of about 0.5 to 10 microns. To the resulting suspension concentrate in a suitable container is then added the propellants, previously cooled to about 25 F. The remainder of the procedure is the same as in Example 2.

Example 4 A self-propelled medicament composition suitable for ophthalmic therapy and containing the following ingredients is prepared as follows:

Weight, g.

Dexamethasone phosphate, disodium 0.027

Ethanol (absolute) 0.300

Dichlorodifluoromethane (Freon 12) 5.136 1,2-dichloro-1,1,2,2-tetrafluoroethane (Freon 114) 9.537

The medicament, previously dried and sterilized, is milled in absolute ethanol to a particle size in the range of about 0.5 to 10 microns and the resulting suspension concentrate diluted with the sterile propellant component in a suitable container and the container sealed as described in Example 2.

Example! 5 A self-propelled medicament composition suitable for ophthalmic therapy and containing the following ingredients is prepared in accordance with the procedure of Example 4:

Weight, g. Prednisolone alcohol 0.050 Ethanol (absolute) 0.150 Dichlorodifluoromethane (Freon 12) 5.18

1,2-dichloro-1,l, 2,2-tetrafiuoroethane (Freon 1'1 4)- 9.62

Example 6 A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared in accordance with the procedure of Example 2:

Weight, g. Epinephrine hydrochloride 0.025 Ethanol (absolute) 0.150 Dichlorodifluoromethane (Freon 12) 5.189

1,2-dich1oro-1,1,2,2-tetrafiuoroethane (Freon 114) 9.636

Example 7 A self-propelled medicament composition suitable for.

both inhalation and ophthalmic therapy and containing the following ingredients is prepared in accordance with the procedure of Example 3, except that the medicament, propellant and container are all sterilized prior to use:

A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared in accordance with the procedure of Example 2:

Weight, g. Dexamethasone phosphate, disodium 0.027 Isoproterenol sulfate 0.011 Ethanol (absolute) 0.450 Dichliorodifiuoromethane(Freon 1 2) 5.079

1,2 dichloro 1,i1,2,2 tetrafluoroethane (Freon Example 9 A self-propelling medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:

Weight Crystalline zinc insulin 400 units (18.2 mg). Ethanol (absolute) 0.280 g. Dichlorodifluoromethane (Freonl-Z) 4.796 g. 1,2 dichloro 1,1,2,2-tetrafluoroethane (Freon 114) 8.906 g.

The crystalline Zinc insulin, previously dried to remove substantially all water, is milled in ethanol to a particle size range approximating 2 microns. To the resulting suspension concentrate in a suitable container is then added the propellants, previously cooled to about 25 F. The remainder of the procedure is the same as in Example 2. Using a 70 mg. metered valve, there will be provided approximately 2 units of crystalline zinc insulin per increment of metered spray. A regimen of ten sprays per day is suitable for the systemic treatment of diabetes and other diseases which respond to insulin therapy.

Example 10 Weight, g. Neomycin sulfate 1.0 Polyrnixin sulfate 1.0 Ethanol (absolute) 0.7

Dichl-orodifluoromethane (Freon 12) 3.9 1,2-dichloro 1,1,2,2-tetrafluoroethane (Freon l-14) 7.35

Using a 70 mg. metered valve, each increment of metered spray will provide approximately 5 mg. of each of the antibiotics for inhalation. A regimen of three applications four times a day is suitable for the treatment of chronic bronchitis, allergic bronchitis and similar disorders.

While the foregoing specification has beenv set forth by way of illustration, it will be understood that various modifications and changes may be made without departing from the spirit and scope of the present invention which is to be limited only by the scope of the appended claims.

I claim:

1. A self-propelling medicament composition consisting essentially of a suspension of a solid, substantially anhydrous medicament in a substantially anhydrous liquid carrier comprised essentially of a mixture of a nontoxic propellant and ethanol, said medicament being substantially insoluble in said mixture of propellant and ethanol and having a particle size in the range of from about 0.5 to about microns, and said ethanol being present in an amount of from about 0.5% to not more than about 5% by weight of said composition, in order to thereby avoid some reflocculation of the dispersed solids caused by higher levels of ethanol.

2. The composition of claim 1 wherein the particle size of the medicament is such that by weight of the particles are inthe range of from about 0.5 to about 4 microns.

3. The composition of claim 2 wherein the ethanol is present inan amount of from about 1 /2 to 3% by weight of saidcomposition.

4. The-composition-of claim3- wherein the medicament is dexamethasone-disodium phosphate.

5. The composition of claim 3 wherein the medicament is isoproterenol sulfate;

6. The composition of claim 3 wherein the medicament is a mixture of dexamethasone and isoproterenol.

7. A package comprising a pressure-tight container having a valve-controlled opening and containing a selfpropelling medicament composition capable of providing a medicament in aerosol form consisting essentially of a suspension of a solid, substantially anhydrous medicament in a substantially anhydrous liquid carrier comprised esentially of a mixture of a non-toxic propellant and ethanol, said medicament being substantially insoluble in said mixture of propellant and ethanol and having a particle size in the range of from about 0.5 to about 10 microns, and said ethanol being present in an amount of from about 0.5% to not more than about 5% by weight of said composition, in order to thereby avoid some refiocculation of the dispersed solids caused by higher levels of ethanol.

8. A method for avoiding some refiocculation of dispersed solids caused by higher levels of ethanol in preparing self-propelled medicament compositions which comprises the steps of drying a solid medicament to remove substantially all water therefrom, reducing said substantially dry medicament to a particle size in the range of from about 0.5 to about 10 microns and suspending said medicament in a substantially anhydrous liquid carrier comprised essentially of a non-toxic propellant and an amount of ethanol suffi-cient to provide from about 0.5% to not more than about 5% by weight of said composition, thereby forming a suspension wherein said medicament is substantially insoluble in said mixture of propellant and ethanol.

References Cited by the Examiner OTHER REFERENCES Abramson: The Role of Particle Size in Inhalation Therapy by Atomization and by Penicillin Dusts, Diseases of the chest 18: 435-449, November 1950.

AMA Archives of Dermatology, vol. 79, No. 1, pp.

103-1 05, entries: Prednisolone in Aerosol Form, Reisset al.; Prednisolone (Meti-Derm) As an Aerosol for Dermatoses,Robinson, January 1959.

Duvenci et al.: Dexamethasone Therapy in Bronchial Asthma, Ann Allergy 17: 695-700, September- October 1959.

Falliers et al.: Dexamethasone in Childhood Asthma," Ann. Allergy 17: NovemberDecember 1959, pp. 887- 894.

(Other references on following page) 9 OTHER REFERENCES Franklin et 211.: Aerosolized Steroids in Bronchial Asthma, J. Allergy 29 (3): 214-221, May 1958.

Lovejoy et al.: Importance of Particle Size in Aerosol Therapy, Proc. Soc. Exp. Biol. Med. 103: 836838, April 1960.

Porush et al.: Pressurized Pharmaceutical Aerosols 10 for Inhalation Therapy, J. Am. Pharm. Assn. (Sci. Ed.), 49 (2): 70-74, February 1960.

Streseman: The Dosage of Dexamethasone and Triarncinolone in Bronchial Asthma, Lancet 2: 257-258, September 5, 1959.

LEWIS GOTTS, Primary Examiner.

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US2782975 *20 Abr 195526 Feb 1957American Cyanamid CoSprayable amorphous antibiotic composition, pressurized container with same, and method of preparing
US2798835 *18 Ene 19549 Jul 1957American Cyanamid CoNewcastle disease and infectious bronchitis vaccines and production thereof
US2798836 *18 Ene 19549 Jul 1957American Cyanamid CoInhalable live virus veterinary vaccine
US2801201 *9 Abr 195330 Jul 1957Lincoln Lab IncBurn treatment filling for pressure packaged dispenser
US2802772 *9 Sep 195413 Ago 1957Merck & Co IncAerosols compositions; bomb, and process for treating flocks of chickens
US2959325 *26 Ago 19548 Nov 1960Risdon Mfg CoMethod and apparatus for dispensing dry powders
US2987439 *7 Ene 19586 Jun 1961William Cooper & Nephews IncMethod of applying an aerosol to the eye
US3014844 *3 Ene 195826 Dic 1961Riker Laboratories IncSelf-propelling powder dispensing compositions
US3028308 *1 Oct 19593 Abr 1962Merck & Co IncDry pharmaceutical vehicle of copolymer of hydrolyzed gelatin and glyoxal, and its production
US3039929 *17 Mar 196019 Jun 1962Abbott LabStable isoproteronol compositions
US3073743 *30 Jul 195915 Ene 1963Upjohn CoAntiinflammatory steroid acetonide compositions and therapy
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US3282791 *17 Ago 19651 Nov 1966Merck & Co IncInhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3482015 *8 Feb 19652 Dic 1969Merck & Co IncAerosol composition of phenylephrine tartrate and the production of such
US3897779 *27 Jun 19735 Ago 1975American Cyanamid CoTriamcinolone acetonide inhalation therapy
US3985868 *13 Ene 197512 Oct 1976American Cyanamid CompanyAsthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US4581225 *28 Ene 19858 Abr 1986Eli Lilly And CompanySustained release intranasal formulation and method of use thereof
US5439670 *2 Jul 19938 Ago 1995Riker Laboratories, Inc.Medicinal aerosol formulations
US5603918 *9 Jun 199518 Feb 1997Boehringer Ingelheim Pharmaceuticals, Inc.Aerosol composition of a salt of ipratropium and a salt of albuterol
US5605674 *31 May 199525 Feb 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5653962 *19 May 19955 Ago 1997Glaxo Group LimitedAerosol formulations containing P134a and particulate medicaments
US5658549 *19 May 199519 Ago 1997Glaxo Group LimitedAerosol formulations containing propellant 134a and fluticasone propionate
US5674471 *19 May 19957 Oct 1997Glaxo Group LimitedAerosol formulations containing P134a and salbutamol
US5674472 *19 May 19957 Oct 1997Glaxo Group LimitedCanisters containing aerosol formulations containing P134a and fluticasone propionate
US5674473 *31 May 19957 Oct 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5676929 *19 May 199514 Oct 1997Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5681545 *31 May 199528 Oct 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5683676 *19 May 19954 Nov 1997Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5683677 *31 May 19954 Nov 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5695743 *4 Mar 19939 Dic 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5720940 *31 May 199524 Feb 1998Riker Laboratories, Inc.Medicinal aerosol formulations
US5736124 *30 May 19957 Abr 1998Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US5744123 *5 Jun 199528 Abr 1998Glaxo Group LimitedAerosol formulations containing P134a and particulate medicaments
US5766573 *16 Ene 199716 Jun 1998Riker Laboratories, Inc.Medicinal aerosol formulations
US5785952 *12 May 199528 Jul 1998Glaxo Group LimitedAerosol medicament formulation having a surface coating of surfactant
US5817293 *30 May 19956 Oct 1998Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5916540 *6 Abr 199829 Jun 1999Glaxo Group LimitedAerosol formulations containing P134A and/or P227 and particulate medicament
US5919435 *12 May 19956 Jul 1999Glaxo Group LimitedAerosol formulation containing a particulate medicament
US5922306 *15 Abr 199813 Jul 1999Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US62005499 Mar 199913 Mar 2001Glaxo Group LimitedAerosol formulation containing P134a and particulate medicament
US622133910 May 199924 Abr 2001Glaxo Group LimitedMedicaments
US62386472 Nov 199929 May 2001Glaxo Group LimitedAerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
US625136817 Jun 199726 Jun 2001Glaxo Group LimitedPharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
US630310314 Jun 200016 Oct 2001Glaxo Group LimitedAerosols containing salmeterol xinafoate and an anticholinergic medicament
US630636824 Nov 199823 Oct 2001Glaxo Group LimitedAerosol formulation containing a particulate medicament
US630636928 Abr 200023 Oct 2001Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US63330231 May 200025 Dic 2001Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US635268428 Abr 19985 Mar 2002Riker Laboratories Inc.CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US674030821 May 200225 May 2004Alexza Molecular Delivery CorporationDelivery of antihistamines through an inhalation route
US674341331 May 19951 Jun 20043M CompanySuspension aerosol formulations
US689362831 Mar 200317 May 2005Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US691906930 Abr 200319 Jul 2005Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US69948431 Abr 20047 Feb 2006Alexza Pharmaceuticals, Inc.Delivery of stimulants through an inhalation route
US700512112 Dic 200328 Feb 2006Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of migraine through an inhalation route
US70051223 Mar 200428 Feb 2006Alexza Pharmaceutical, Inc.Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US700861512 Dic 20037 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of anti-migraine compounds through an inhalation route
US70086161 Abr 20047 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of stimulants through an inhalation route
US70118193 Mar 200414 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of rizatriptan or zolmitriptan through an inhalation route
US70118201 Abr 200414 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of Parkinsons through an inhalation route
US70148403 Mar 200421 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US701484131 Mar 200421 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of antiemetics through an inhalation route
US701861912 Dic 200328 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US70186209 Feb 200428 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of beta-blockers through an inhalation route
US70186213 Mar 200428 Mar 2006Alexza Pharmaceuticals, Inc.Delivery of rizatriptan or zolmitriptan through an inhalation route
US702231231 Mar 20044 Abr 2006Alexza Pharmaceuticals, Inc.Delivery of antiemetics through an inhalation route
US702965812 Dic 200318 Abr 2006Alexza Pharmaceuticals, Inc.Delivery of antidepressants through an inhalation route
US703357530 Ene 200425 Abr 2006Alexza Pharmaceuticals, Inc.Delivery of physiologically active compounds through an inhalation route
US704511827 Ene 200416 May 2006Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of migraine through an inhalation route
US70451193 Mar 200416 May 2006Alexza Pharmaceuticals, Inc.Delivery of diazepam through an inhalation route
US70489099 Feb 200423 May 2006Alexza Pharmaceuticals, Inc.Delivery of beta-blockers through an inhalation route
US705267928 Ene 200430 May 2006Alexza Pharmaceuticals, Inc.Delivery of antipsychotics through an inhalation route
US70526801 Abr 200430 May 2006Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of Parkinsons through an inhalation route
US706025427 Ene 200413 Jun 2006Alexza Pharmaceuticals, Inc.Delivery of antidepressants through an inhalation route
US706025529 Ene 200413 Jun 2006Alexza Pharmaceuticals, Inc.Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US706383029 Ene 200420 Jun 2006Alexza Pharmaceuticals, Inc.Delivery of anti-migraine compounds through an inhalation route
US706383129 Ene 200420 Jun 2006Alexza Pharmaceuticals, Inc.Delivery of erectile dysfunction drugs through an inhalation route
US706383231 Mar 200420 Jun 2006Alexza Pharmaceuticals, Inc.Delivery of muscle relaxants through an inhalation route
US706711429 Ene 200427 Jun 2006Alexza Pharmaceuticals, Inc.Delivery of antihistamines through an inhalation route
US707076112 Dic 20034 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US707076212 Dic 20034 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of analgesics through an inhalation route
US707076327 Ene 20044 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of diphenhydramine through an inhalation route
US707076427 Ene 20044 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of analgesics through an inhalation route
US707076529 Ene 20044 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of drug esters through an inhalation route
US707076630 Ene 20044 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of physiologically active compounds through an inhalation route
US707801730 Dic 200318 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of sedative-hypnotics through an inhalation route
US707801830 Dic 200318 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of opioids through an inhalation route
US707801930 Dic 200318 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of drug esters through an inhalation route
US707802030 Dic 200318 Jul 2006Alexza Pharmaceuticals, Inc.Delivery of antipsychotics through an inhalation route
US708721627 Ene 20048 Ago 2006Rabinowitz Joshua DDelivery of sedative-hypnotics through an inhalation route
US708721727 Ene 20048 Ago 2006Alexza Pharmaceuticals, Inc.Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US70872183 Mar 20048 Ago 2006Alexza Pharmaceuticals, Inc.Delivery of diazepam through an inhalation route
US709083020 Nov 200315 Ago 2006Alexza Pharmaceuticals, Inc.Drug condensation aerosols and kits
US709439230 Dic 200322 Ago 2006Alexza Pharmaceuticals, Inc.Delivery of antihistamines through an inhalation route
US710153431 May 19955 Sep 20063M Innovative Properties CompanySuspension aerosol formulations
US710515231 May 199512 Sep 20063M Innovative Properties CompanySuspension aerosol formulations
US710884731 Mar 200419 Sep 2006Alexza Pharmaceuticals, Inc.Delivery of muscle relaxants through an inhalation route
US711525030 Dic 20033 Oct 2006Alexza Pharmaceuticals, Inc.Delivery of erectile dysfunction drugs through an inhalation route
US71605383 Sep 20049 Ene 2007Boehringer Ingelheim KgSuspension aerosol formulations of pharmaceutical products
US716937829 Ene 200430 Ene 2007Alexza Pharmaceuticals, Inc.Delivery of opioids through an inhalation route
US737478225 Oct 200120 May 2008Baxter International Inc.Production of microspheres
US74423687 Mar 200628 Oct 2008Alexza Pharmaceuticals, Inc.Delivery of stimulants through an inhalation route
US74457687 Ago 20064 Nov 2008Alexza Pharmaceuticals, Inc.Delivery of sedative-hypnotics through an inhalation route
US74491724 Abr 200611 Nov 2008Alexza Pharmaceuticals, Inc.Delivery of antiemetics through an inhalation route
US744917313 Jun 200611 Nov 2008Alexza Pharmaceuticals, Inc.Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US744917430 Jun 200611 Nov 2008Alexza Pharmaceuticals, Inc.Delivery of analgesics through an inhalation route
US74491755 Jul 200611 Nov 2008Alexza Pharmaceuticals, Inc.Delivery of erectile dysfunction drugs through an inhalation route
US745837413 May 20022 Dic 2008Alexza Pharmaceuticals, Inc.Method and apparatus for vaporizing a compound
US746543524 May 200616 Dic 2008Alexza Pharmaceuticals, Inc.Delivery of beta-blockers through an inhalation route
US746543630 May 200616 Dic 2008Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of Parkinson's through an inhalation route
US746543716 Jun 200616 Dic 2008Alexza Pharmaceuticals, Inc.Delivery of anti-migraine compounds through an inhalation route
US74681799 Ene 200723 Dic 2008Alexza Pharmaceuticals, Inc.Delivery of opioids through an inhalation route
US74704217 Ago 200630 Dic 2008Alexza Pharmaceuticals, IncDelivery of diazepam through an inhalation route
US748528513 Jun 20063 Feb 2009Alexza Pharmaceuticals, Inc.Delivery of antidepressants through an inhalation route
US749104722 Ago 200617 Feb 2009Alexza Pharmaceuticals, Inc.Delivery of antihistamines through an inhalation route
US749801921 Mar 20063 Mar 2009Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of headache through an inhalation route
US749802023 Nov 20043 Mar 2009Glaxo Group LimitedMedicaments
US750739719 Sep 200624 Mar 2009Alexza Pharmaceuticals, Inc.Delivery of muscle relaxants through an inhalation route
US75107027 Ago 200631 Mar 2009Alexza Pharmaceuticals, Inc.Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US751940817 Nov 200414 Abr 2009Dexcom, Inc.Integrated receiver for continuous analyte sensor
US752448430 Jun 200628 Abr 2009Alexza Pharmaceuticals, Inc.Delivery of diphenhydramine through an inhalation route
US753700913 May 200226 May 2009Alexza Pharmaceuticals, Inc.Method of forming an aerosol for inhalation delivery
US75402863 Jun 20042 Jun 2009Alexza Pharmaceuticals, Inc.Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US755013320 Nov 200323 Jun 2009Alexza Pharmaceuticals, Inc.Respiratory drug condensation aerosols and methods of making and using them
US758154012 Ago 20041 Sep 2009Alexza Pharmaceuticals, Inc.Aerosol drug delivery device incorporating percussively activated heat packages
US758228414 Abr 20031 Sep 2009Nektar TherapeuticsParticulate materials
US758399014 Abr 20081 Sep 2009Dexcom, Inc.System and methods for processing analyte sensor data
US75854934 Ago 20038 Sep 2009Alexza Pharmaceuticals, Inc.Thin-film drug delivery article and method of use
US7591801 *26 Feb 200422 Sep 2009Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US759972614 Abr 20086 Oct 2009Dexcom, Inc.System and methods for processing analyte sensor data
US760133718 Jul 200613 Oct 2009Alexza Pharmaceuticals, Inc.Delivery of antipsychotics through an inhalation route
US763786811 Ene 200529 Dic 2009Dexcom, Inc.Composite material for implantable device
US764004822 Feb 200629 Dic 2009Dexcom, Inc.Analyte sensor
US76454424 Ago 200312 Ene 2010Alexza Pharmaceuticals, Inc.Rapid-heating drug delivery article and method of use
US76572973 May 20042 Feb 2010Dexcom, Inc.Implantable analyte sensor
US77158933 Dic 200411 May 2010Dexcom, Inc.Calibration techniques for a continuous analyte sensor
US776601326 Oct 20013 Ago 2010Alexza Pharmaceuticals, Inc.Aerosol generating method and device
US77713521 May 200810 Ago 2010Dexcom, Inc.Low oxygen in vivo analyte sensor
US77786801 Ago 200317 Ago 2010Dexcom, Inc.System and methods for processing analyte sensor data
US778333310 Mar 200524 Ago 2010Dexcom, Inc.Transcutaneous medical device with variable stiffness
US779702814 Abr 200814 Sep 2010Dexcom, Inc.System and methods for processing analyte sensor data
US782698118 Ene 20052 Nov 2010Dexcom, Inc.System and methods for processing analyte sensor data
US785776022 Feb 200628 Dic 2010Dexcom, Inc.Analyte sensor
US78605447 Mar 200728 Dic 2010Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US78698536 Ago 201011 Ene 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US788569710 Mar 20058 Feb 2011Dexcom, Inc.Transcutaneous analyte sensor
US78856996 Ago 20108 Feb 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US78968093 Nov 20081 Mar 2011Dexcom, Inc.Dual electrode system for a continuous analyte sensor
US789951117 Ene 20061 Mar 2011Dexcom, Inc.Low oxygen in vivo analyte sensor
US79013541 May 20088 Mar 2011Dexcom, Inc.Low oxygen in vivo analyte sensor
US790583321 Jun 200515 Mar 2011Dexcom, Inc.Transcutaneous analyte sensor
US791368820 May 200329 Mar 2011Alexza Pharmaceuticals, Inc.Inhalation device for producing a drug aerosol
US79144503 May 201029 Mar 2011Dexcom, Inc.System and methods for processing analyte sensor data
US791718616 Nov 200929 Mar 2011Dexcom, Inc.Calibration techniques for a continuous analyte sensor
US79209069 Mar 20065 Abr 2011Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US79209077 Jun 20075 Abr 2011Abbott Diabetes Care Inc.Analyte monitoring system and method
US792532123 Mar 201012 Abr 2011Dexcom, Inc.System and methods for processing analyte sensor data
US792727429 Jul 200819 Abr 2011Dexcom, Inc.Integrated receiver for continuous analyte sensor
US793363923 Mar 201026 Abr 2011Dexcom, Inc.System and methods for processing analyte sensor data
US793505714 Ene 20093 May 2011Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US794214713 May 200217 May 2011Alexza Pharmaceuticals, Inc.Aerosol forming device for use in inhalation therapy
US794938111 Abr 200824 May 2011Dexcom, Inc.Transcutaneous analyte sensor
US795526123 Mar 20107 Jun 2011Dexcom, Inc.System and methods for processing analyte sensor data
US795956923 Mar 201014 Jun 2011Dexcom, Inc.System and methods for processing analyte sensor data
US79764926 Ago 200912 Jul 2011Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US797677822 Jun 200512 Jul 2011Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US797910426 May 201012 Jul 2011Dexcom, Inc.System and methods for processing analyte sensor data
US79814012 Feb 200719 Jul 2011Alexza Pharmaceuticals, Inc.Diuretic aerosols and methods of making and using them
US798698623 Mar 201026 Jul 2011Dexcom, Inc.System and methods for processing analyte sensor data
US798784621 Nov 20082 Ago 2011Alexza Pharmaceuticals, Inc.Method and apparatus for vaporizing a compound
US798895227 Mar 20082 Ago 2011Alexza Pharmaceuticals, Inc.Delivery of drug esters through an inhalation route
US799419726 Ago 20099 Ago 2011Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US799807114 Oct 200916 Ago 2011Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US80009019 Ago 201016 Ago 2011Dexcom, Inc.Transcutaneous analyte sensor
US800308013 May 200323 Ago 2011Alexza Pharmaceuticals, Inc.Delivery of drug amines through an inhalation route
US800552424 Mar 201023 Ago 2011Dexcom, Inc.Signal processing for continuous analyte sensor
US800552514 Oct 200923 Ago 2011Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US801017422 Ago 200330 Ago 2011Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US805260120 Ago 20088 Nov 2011Dexcom, Inc.System and methods for processing analyte sensor data
US80601731 Ago 200315 Nov 2011Dexcom, Inc.System and methods for processing analyte sensor data
US807351914 Oct 20096 Dic 2011Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US807352025 May 20106 Dic 2011Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US807464422 May 200913 Dic 2011Alexza Pharmaceuticals, Inc.Method of forming an aerosol for inhalation delivery
US808023612 Jun 200920 Dic 2011Nektar Therapeutics Uk, LtdParticulate materials
US811963919 Jul 201021 Feb 2012Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8124057 *26 Ene 200928 Feb 2012Alkermes Pharma Ireland LimitedPropellant-based nanoparticulate dry powder aerosols and method of making
US812856214 Oct 20096 Mar 2012Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US814837711 Feb 20083 Abr 2012Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US815048814 Oct 20093 Abr 2012Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US816066911 Abr 200717 Abr 2012Dexcom, Inc.Transcutaneous analyte sensor
US81606711 Sep 201017 Abr 2012Dexcom, Inc.Calibration techniques for a continuous analyte sensor
US816282930 Mar 200924 Abr 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US816780125 Mar 20101 May 2012Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US817080310 Mar 20051 May 2012Dexcom, Inc.Transcutaneous analyte sensor
US817310727 Mar 20098 May 2012Alexza Pharmaceuticals, Inc.Delivery of antipsychotics through an inhalation route
US81756739 Nov 20098 May 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US817771621 Dic 200915 May 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US81952659 Feb 20115 Jun 2012Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US820629716 Dic 200926 Jun 2012Dexcom, Inc.System and methods for processing analyte sensor data
US821613923 Sep 200910 Jul 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US822441310 Oct 200817 Jul 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822655518 Mar 200924 Jul 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822655728 Dic 200924 Jul 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822655827 Sep 201024 Jul 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822953520 Feb 200924 Jul 2012Dexcom, Inc.Systems and methods for blood glucose monitoring and alert delivery
US822953627 May 201024 Jul 2012Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US82315311 Jun 200631 Jul 2012Dexcom, Inc.Analyte sensor
US823153230 Abr 200731 Jul 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US823395812 Oct 200931 Jul 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US82339591 Sep 200631 Jul 2012Dexcom, Inc.Systems and methods for processing analyte sensor data
US82350378 May 20087 Ago 2012Alexza Pharmaceuticals, Inc.Drug condensation aerosols and kits
US823589621 Dic 20097 Ago 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US823624212 Feb 20107 Ago 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US82496841 Sep 201021 Ago 2012Dexcom, Inc.Calibration techniques for a continuous analyte sensor
US825190615 Abr 200928 Ago 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US825503117 Mar 200928 Ago 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US825725916 Oct 20084 Sep 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US82603929 Jun 20084 Sep 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US826039313 Jun 20074 Sep 2012Dexcom, Inc.Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US826572512 Oct 200911 Sep 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US82657269 Nov 200911 Sep 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US826824328 Dic 200918 Sep 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US827302213 Feb 200925 Sep 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US827543723 Mar 200725 Sep 2012Dexcom, Inc.Transcutaneous analyte sensor
US82754399 Nov 200925 Sep 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US828047523 Feb 20092 Oct 2012Dexcom, Inc.Transcutaneous analyte sensor
US82825498 Dic 20049 Oct 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US828255029 Jul 20089 Oct 2012Dexcom, Inc.Integrated receiver for continuous analyte sensor
US828535423 Mar 20109 Oct 2012Dexcom, Inc.System and methods for processing analyte sensor data
US82874537 Nov 200816 Oct 2012Dexcom, Inc.Analyte sensor
US828745427 Sep 201016 Oct 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US828837220 Nov 200316 Oct 2012Alexza Pharmaceuticals, Inc.Method for treating headache with loxapine
US829055924 Oct 200816 Oct 2012Dexcom, Inc.Systems and methods for processing sensor data
US829056018 Nov 200816 Oct 2012Dexcom, Inc.Transcutaneous analyte sensor
US829056123 Sep 200916 Oct 2012Dexcom, Inc.Signal processing for continuous analyte sensor
US82905623 May 201016 Oct 2012Dexcom, Inc.System and methods for processing analyte sensor data
US829281027 Ene 201123 Oct 2012Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US83065989 Nov 20096 Nov 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US831174926 May 201113 Nov 2012Dexcom, Inc.Transcutaneous analyte sensor
US832114929 Jun 201127 Nov 2012Dexcom, Inc.Transcutaneous analyte sensor
US833200823 Mar 201011 Dic 2012Dexcom, Inc.System and methods for processing analyte sensor data
US833319729 May 200918 Dic 2012Alexza Pharmaceuticals, Inc.Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US834633618 Mar 20091 Ene 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US834633730 Jun 20091 Ene 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US834633827 Ene 20111 Ene 2013Dexcom, Inc.System and methods for replacing signal artifacts in a glucose sensor data stream
US835382921 Dic 200915 Ene 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US835709121 Dic 200922 Ene 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US836661430 Mar 20095 Feb 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US83677347 May 20105 Feb 2013Amphastar Pharmaceuticals Inc.Stable epinephrine suspension formulation with high inhalation delivery efficiency
US836991924 Oct 20085 Feb 2013Dexcom, Inc.Systems and methods for processing sensor data
US837200521 Dic 200912 Feb 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US837466716 Oct 200812 Feb 2013Dexcom, Inc.Signal processing for continuous analyte sensor
US838027311 Abr 200919 Feb 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US83860047 Sep 201126 Feb 2013Dexcom, Inc.Calibration techniques for a continuous analyte sensor
US838761216 Jun 20095 Mar 2013Alexza Pharmaceuticals, Inc.Self-contained heating unit and drug-supply unit employing same
US839194517 Mar 20095 Mar 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US83940211 Oct 200712 Mar 2013Dexcom, Inc.System and methods for processing analyte sensor data
US839652825 Mar 200812 Mar 2013Dexcom, Inc.Analyte sensor
US84091317 Mar 20072 Abr 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US84123019 Feb 20112 Abr 2013Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US841731224 Oct 20089 Abr 2013Dexcom, Inc.Systems and methods for processing sensor data
US842311324 Oct 200816 Abr 2013Dexcom, Inc.Systems and methods for processing sensor data
US842867816 May 201223 Abr 2013Dexcom, Inc.Calibration techniques for a continuous analyte sensor
US842867926 Mar 201023 Abr 2013Dexcom, Inc.System and methods for processing analyte sensor data
US843517927 Ene 20117 May 2013Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US844261021 Ago 200814 May 2013Dexcom, Inc.System and methods for processing analyte sensor data
US846023111 Jul 201111 Jun 2013Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US846335014 May 201011 Jun 2013Dexcom, Inc.Transcutaneous analyte sensor
US846542530 Jun 200918 Jun 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US846988623 Sep 200925 Jun 2013Dexcom, Inc.Signal processing for continuous analyte sensor
US847030111 Nov 201125 Jun 2013Nektar TherapeuticsParticulate materials
US847302131 Jul 200925 Jun 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US848058019 Abr 20079 Jul 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US848379111 Abr 20089 Jul 2013Dexcom, Inc.Transcutaneous analyte sensor
US848379329 Oct 20109 Jul 2013Dexcom, Inc.Dual electrode system for a continuous analyte sensor
US849147427 Ene 201123 Jul 2013Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US850693523 Jun 200913 Ago 2013Alexza Pharmaceuticals, Inc.Respiratory drug condensation aerosols and methods of making and using them
US851551610 Mar 200520 Ago 2013Dexcom, Inc.Transcutaneous analyte sensor
US854855114 May 20101 Oct 2013Dexcom, Inc.Transcutaneous analyte sensor
US854855322 Jun 20121 Oct 2013Dexcom, Inc.System and methods for processing analyte sensor data
US856003726 Mar 201015 Oct 2013Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US856003917 Sep 200915 Oct 2013Dexcom, Inc.Particle-containing membrane and particulate electrode for analyte sensors
US85625585 Jun 200822 Oct 2013Dexcom, Inc.Integrated medicament delivery device for use with continuous analyte sensor
US85658487 May 200922 Oct 2013Dexcom, Inc.Transcutaneous analyte sensor
US856584914 May 201022 Oct 2013Dexcom, Inc.Transcutaneous analyte sensor
US857162514 May 201029 Oct 2013Dexcom, Inc.Transcutaneous analyte sensor
US85798167 Ene 201012 Nov 2013Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US858888216 Dic 200919 Nov 2013Dexcom, Inc.System and methods for processing analyte sensor data
US859145520 Feb 200926 Nov 2013Dexcom, Inc.Systems and methods for customizing delivery of sensor data
US85971893 Mar 20093 Dic 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8597616 *22 Oct 20083 Dic 2013Board Of Regents Of The University Of Texas SystemDry powder drug delivery formulations, methods of use, and devices therefore
US86119787 Ene 201017 Dic 2013Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US861215916 Feb 200417 Dic 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US861707121 Jun 200731 Dic 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US862290511 Dic 20097 Ene 2014Dexcom, Inc.System and methods for processing analyte sensor data
US862290621 Dic 20097 Ene 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US864161921 Dic 20094 Feb 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US86498413 Abr 200711 Feb 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US865204320 Jul 201218 Feb 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US865774516 Oct 200825 Feb 2014Dexcom, Inc.Signal processing for continuous analyte sensor
US86577475 Abr 201125 Feb 2014Dexcom, Inc.Systems and methods for processing analyte sensor data
US866062717 Mar 200925 Feb 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US866310929 Mar 20104 Mar 2014Dexcom, Inc.Transcutaneous analyte sensor
US866646916 Nov 20074 Mar 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US86686453 Ene 200311 Mar 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US867081530 Abr 200711 Mar 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US867284427 Feb 200418 Mar 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US867284525 Mar 201018 Mar 2014Dexcom, Inc.Systems and methods for processing analyte sensor data
US867628711 Dic 200918 Mar 2014Dexcom, Inc.System and methods for processing analyte sensor data
US868818830 Jun 20091 Abr 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US869077511 Abr 20088 Abr 2014Dexcom, Inc.Transcutaneous analyte sensor
US87001178 Dic 200915 Abr 2014Dexcom, Inc.System and methods for processing analyte sensor data
US872158530 Mar 201213 May 2014Dex Com, Inc.Integrated delivery device for continuous glucose sensor
US873163022 Mar 201020 May 2014Dexcom, Inc.Transcutaneous analyte sensor
US873434630 Abr 200727 May 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US873434817 Mar 200927 May 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US87381093 Mar 200927 May 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US87445453 Mar 20093 Jun 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US874731523 Sep 200910 Jun 2014Dexcom. Inc.Signal processing for continuous analyte sensor
US87509552 Nov 200910 Jun 2014Dexcom, Inc.Analyte sensor
US876185627 Abr 201224 Jun 2014Dexcom, Inc.System and methods for processing analyte sensor data
US876505927 Oct 20101 Jul 2014Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US877118731 May 20118 Jul 2014Dexcom, Inc.System and methods for processing analyte sensor data
US877488724 Mar 20078 Jul 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US877488820 Ene 20108 Jul 2014Dexcom, Inc.System and methods for processing analyte sensor data
US87778534 Abr 201215 Jul 2014Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US878800611 Dic 200922 Jul 2014Dexcom, Inc.System and methods for processing analyte sensor data
US87880078 Mar 201222 Jul 2014Dexcom, Inc.Transcutaneous analyte sensor
US878800831 May 201122 Jul 2014Dexcom, Inc.System and methods for processing analyte sensor data
US879026014 Oct 200929 Jul 2014Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US879295319 Mar 201029 Jul 2014Dexcom, Inc.Transcutaneous analyte sensor
US879295419 Mar 201029 Jul 2014Dexcom, Inc.Transcutaneous analyte sensor
US87929559 Jun 201129 Jul 2014Dexcom, Inc.Transcutaneous analyte sensor
US879517714 Ene 20095 Ago 2014Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US880161024 Jul 200912 Ago 2014Dexcom, Inc.Signal processing for continuous analyte sensor
US880161227 Abr 201212 Ago 2014Dexcom, Inc.System and methods for processing analyte sensor data
US880818227 Abr 201219 Ago 2014Dexcom, Inc.System and methods for processing analyte sensor data
US88082285 Jun 200819 Ago 2014Dexcom, Inc.Integrated medicament delivery device for use with continuous analyte sensor
US881207217 Abr 200819 Ago 2014Dexcom, Inc.Transcutaneous medical device with variable stiffness
US88120731 Jun 201019 Ago 2014Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US88214009 Feb 20112 Sep 2014Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US882512714 May 20102 Sep 2014Dexcom, Inc.Transcutaneous analyte sensor
US88283593 Jun 20139 Sep 2014Nektar TherapeuticsParticulate materials
US884055326 Feb 200923 Sep 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US88431871 Jun 201023 Sep 2014Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US884553611 Abr 200730 Sep 2014Dexcom, Inc.Transcutaneous analyte sensor
US885843410 Mar 200514 Oct 2014Dexcom, Inc.Transcutaneous analyte sensor
US888013718 Abr 20034 Nov 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US888274130 Abr 201211 Nov 2014Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US88862737 Nov 200811 Nov 2014Dexcom, Inc.Analyte sensor
US89158493 Feb 200923 Dic 2014Dexcom, Inc.Transcutaneous analyte sensor
US891585028 Mar 201423 Dic 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US892031928 Dic 201230 Dic 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US892040130 Abr 201230 Dic 2014Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US892658530 Mar 20126 Ene 2015Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US895551227 Mar 201317 Feb 2015Alexza Pharmaceuticals, Inc.Method of forming an aerosol for inhalation delivery
US89743861 Nov 200510 Mar 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US898620913 Jul 201224 Mar 2015Dexcom, Inc.Transcutaneous analyte sensor
US89913874 Mar 201331 Mar 2015Alexza Pharmaceuticals, Inc.Self-contained heating unit and drug-supply unit employing same
US901133129 Dic 200421 Abr 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US901133230 Oct 200721 Abr 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US90147737 Mar 200721 Abr 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US902057210 Sep 201028 Abr 2015Dexcom, Inc.Systems and methods for processing, transmitting and displaying sensor data
US90429532 Mar 200726 May 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US904419910 Mar 20052 Jun 2015Dexcom, Inc.Transcutaneous analyte sensor
US905041330 Abr 20129 Jun 2015Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US905590114 Sep 201216 Jun 2015Dexcom, Inc.Transcutaneous analyte sensor
US906074219 Mar 201023 Jun 2015Dexcom, Inc.Transcutaneous analyte sensor
US90666943 Abr 200730 Jun 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US906669512 Abr 200730 Jun 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US906669727 Oct 201130 Jun 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US907247721 Jun 20077 Jul 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US907860717 Jun 201314 Jul 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US907860813 Jul 201214 Jul 2015Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US910762315 Abr 200918 Ago 2015Dexcom, Inc.Signal processing for continuous analyte sensor
US913540224 Oct 200815 Sep 2015Dexcom, Inc.Systems and methods for processing sensor data
US914356920 Feb 200922 Sep 2015Dexcom, Inc.Systems and methods for processing, transmitting and displaying sensor data
US91492199 Feb 20116 Oct 2015Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US914923313 Jun 20126 Oct 2015Dexcom, Inc.Systems and methods for processing sensor data
US914923413 Jun 20126 Oct 2015Dexcom, Inc.Systems and methods for processing sensor data
US915549618 Feb 201113 Oct 2015Dexcom, Inc.Low oxygen in vivo analyte sensor
US915584326 Jul 201213 Oct 2015Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US919232823 Sep 200924 Nov 2015Dexcom, Inc.Signal processing for continuous analyte sensor
US92113827 Ago 201215 Dic 2015Alexza Pharmaceuticals, Inc.Drug condensation aerosols and kits
US92204499 Jul 201329 Dic 2015Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US92479012 Ago 20062 Feb 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US928292525 Mar 201015 Mar 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US930820830 Jul 201012 Abr 2016Alexza Pharmaceuticals, Inc.Aerosol generating method and device
US93141967 Sep 201219 Abr 2016Dexcom, Inc.System and methods for processing analyte sensor data for sensor calibration
US932671429 Jun 20103 May 2016Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US93267165 Dic 20143 May 2016Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US933922231 May 201317 May 2016Dexcom, Inc.Particle-containing membrane and particulate electrode for analyte sensors
US933923816 May 201217 May 2016Dexcom, Inc.Systems and methods for processing sensor data
US935166812 Oct 200931 May 2016Dexcom, Inc.Signal processing for continuous analyte sensor
US936417323 Sep 200914 Jun 2016Dexcom, Inc.Signal processing for continuous analyte sensor
US937062931 Mar 201521 Jun 2016Alexza Pharmaceuticals, Inc.Self-contained heating unit and drug-supply unit employing same
US941477710 Mar 200516 Ago 2016Dexcom, Inc.Transcutaneous analyte sensor
US94209651 Jul 201123 Ago 2016Dexcom, Inc.Signal processing for continuous analyte sensor
US94209684 Abr 201223 Ago 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US942718312 Jul 201130 Ago 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US943990711 Nov 201313 Sep 2016Alexza Pharmaceutical, Inc.Method of forming an aerosol for inhalation delivery
US944003413 Nov 201313 Sep 2016Alexza Pharmaceuticals, Inc.Drug condensation aerosols and kits
US944619426 Mar 201020 Sep 2016Dexcom, Inc.Methods and systems for promoting glucose management
US945190819 Dic 201227 Sep 2016Dexcom, Inc.Analyte sensor
US945191027 Ago 201027 Sep 2016Dexcom, Inc.Transcutaneous analyte sensor
US947781123 Jun 200525 Oct 2016Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US949815516 Oct 200822 Nov 2016Dexcom, Inc.Signal processing for continuous analyte sensor
US949815930 Oct 200722 Nov 2016Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US95107824 Abr 20126 Dic 2016Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US953894625 Mar 201010 Ene 2017Dexcom, Inc.Integrated receiver for continuous analyte sensor
US95856074 Abr 20127 Mar 2017Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US96100349 Nov 20154 Abr 2017Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US96160604 Ago 201411 Abr 2017Nektar TherapeuticsParticulate materials
US964906929 Jun 201616 May 2017Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US966868218 Dic 20146 Jun 2017Dexcom, Inc.Transcutaneous analyte sensor
US968748713 Nov 201327 Jun 2017Alexza Pharmaceuticals, Inc.Aerosol forming device for use in inhalation therapy
US971744915 Ene 20131 Ago 2017Dexcom, Inc.Systems and methods for processing sensor data
US972402824 Nov 20148 Ago 2017Dexcom, Inc.Analyte sensor
US97240456 Abr 20178 Ago 2017Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US97411399 Ago 201322 Ago 2017Dexcom, Inc.Integrated medicament delivery device for use with continuous analyte sensor
US975044115 Ago 20165 Sep 2017Dexcom, Inc.Signal processing for continuous analyte sensor
US975046014 Abr 20175 Sep 2017Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US97570611 Sep 201512 Sep 2017Dexcom, Inc.Low oxygen in vivo analyte sensor
US977554330 Dic 20133 Oct 2017Dexcom, Inc.Transcutaneous analyte sensor
US980157218 Jun 201531 Oct 2017Dexcom, Inc.Transcutaneous analyte sensor
US20030032632 *21 Dic 200013 Feb 2003Crispps Leslie AlanPharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US20030059474 *17 Sep 200227 Mar 2003Scott Terrence L.Sustained release microspheres
US20030064033 *16 Ago 20023 Abr 2003Brown Larry R.Propellant-based microparticle formulations
US20030143163 *11 Mar 200331 Jul 2003Glaxo Group LimitedMedicaments
US20030165437 *31 Mar 20034 Sep 2003Glaxo Group LimitedAerosos formulations containing P134a and particulate medicament
US20030198600 *30 Abr 200323 Oct 2003Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20030232876 *16 Abr 200318 Dic 2003Pozen, Inc.Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US20040126326 *12 Dic 20031 Jul 2004Alexza Molecular Delivery CorporationDelivery of antidepressants through an inhalation route
US20040126327 *12 Dic 20031 Jul 2004Alexza Molecular Delivery CorporationDelivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20040126328 *12 Dic 20031 Jul 2004Alexza Molecular Delivery CorporationDelivery of compounds for the treatment of migraine through an inhalation route
US20040126329 *12 Dic 20031 Jul 2004Alexza Molecular Delivery CorporationDelivery of analgesics through an inhalation route
US20040127481 *12 Dic 20031 Jul 2004Alexza Molecular Delivery CorporationDelivery of anti-migraine compounds through an inhalation route
US20040127490 *12 Dic 20031 Jul 2004Alexza Molecular Delivery CorporationDelivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US20040156788 *30 Dic 200312 Ago 2004Alexza Molecular Delivery CorporationDelivery of erectile dysfunction drugs through an inhalation route
US20040157815 *10 Feb 200412 Ago 2004Smithkline Beecham CorporationPharmaceutical formulation of fluticasone propionate
US20040161385 *9 Feb 200419 Ago 2004Alexza Molecular Delivery CorporationDelivery of beta-blockers through an inhalation route
US20040167228 *9 Feb 200426 Ago 2004Alexza Molecular Delivery CorporationDelivery of beta-blockers through an inhalation route
US20040170570 *3 Mar 20042 Sep 2004Alexza Molecular Delivery CorporationDelivery of rizatriptan or zolmitriptan through an inhalation route
US20040170571 *3 Mar 20042 Sep 2004Alexza Molecular Delivery CorporationDelivery of diazepam through an inhalation route
US20040170572 *3 Mar 20042 Sep 2004Alexza Molecular Delivery CorporationDelivery of rizatriptan or zolmitriptan through an inhalation route
US20040170573 *3 Mar 20042 Sep 2004Alexza Molecular Delivery CorporationDelivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US20040171609 *3 Mar 20042 Sep 2004Alexza Molecular Delivery CorporationDelivery of diazepam through an inhalation route
US20040184996 *27 Ene 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20040184999 *29 Ene 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of anti-migraine compounds through an inhalation route
US20040185000 *29 Ene 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of antihistamines through an inhalation route
US20040185001 *30 Ene 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of physiologically active compounds through an inhalation route
US20040185003 *29 Ene 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20040185004 *29 Ene 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of erectile dysfunction drugs through an inhalation route
US20040185005 *31 Mar 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of antiemetics through an inhalation route
US20040185006 *1 Abr 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of stimulants through an inhalation route
US20040185007 *1 Abr 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of compounds for the treatment of Parkinsons through an inhalation route
US20040185008 *1 Abr 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of compounds for the treatment of parkinsons through an inhalation route
US20040186130 *31 Mar 200423 Sep 2004Alexza Molecular Delivery CorporationDelivery of muscle relaxants through an inhalation route
US20040191179 *27 Ene 200430 Sep 2004Alexza Molecular Delivery CorporationDelivery of antidepressants through an inhalation route
US20040191180 *27 Ene 200430 Sep 2004Alexza Molecular Delivery CorporationDelivery of compounds for the treatment of migraine through an inhalation route
US20040191181 *27 Ene 200430 Sep 2004Alexza Molecular Delivery CorporationDelivery of diphenhydramine through an inhalation route
US20040191182 *27 Ene 200430 Sep 2004Alexza Molecular Delivery CorporationDelivery of analgesics through an inhalation route
US20040191183 *31 Mar 200430 Sep 2004Alexza Molecular Delivery CorporationDelivery of antiemetics through an inhalation route
US20040197273 *9 Abr 20047 Oct 20043M CompanySuspension aerosol formulations
US20040202617 *29 Ene 200414 Oct 2004Alexza Molecular Delivery CorporationDelivery of opioids through an inhalation route
US20050031548 *3 Sep 200410 Feb 2005Boehringer Ingelheim KgSuspension aerosol formulations of pharmaceutical products
US20050048001 *15 Sep 20043 Mar 2005Cripps Alan LesliePharmaceutical formulations of salmeterol
US20050089477 *23 Nov 200428 Abr 2005Glaxo Group LimitedMedicaments
US20050207991 *9 May 200522 Sep 2005Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US20050232873 *21 Jun 200520 Oct 2005Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20060233719 *13 Jun 200619 Oct 2006Alexza Pharmaceuticals, Inc.Delivery of antidepressants through an inhalation route
US20060269486 *7 Ago 200630 Nov 2006Alexza Pharmaceuticals, Inc.Delivery of diazepam through an inhalation route
US20060286042 *7 Ago 200621 Dic 2006Alexza Pharmaceuticals, Inc.Delivery of sedative-hypnotics through an inhalation route
US20070020196 *30 Jun 200625 Ene 2007Pipkin James DInhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299 *30 Jun 200625 Ene 2007Pipkin James DInhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070160542 *19 Dic 200612 Jul 2007Verus Pharmaceuticals, Inc.Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049 *19 Dic 20062 Ago 2007Verus Pharmaceuticals, Inc.Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178050 *19 Dic 20062 Ago 2007Verus Pharmaceuticals, Inc.Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070185066 *19 Dic 20069 Ago 2007Verus Pharmaceuticals, Inc.Systems and methods for the delivery of corticosteroids
US20070197486 *19 Dic 200623 Ago 2007Verus Pharmaceuticals, Inc.Methods and systems for the delivery of corticosteroids
US20070197487 *19 Dic 200623 Ago 2007Verus Pharmaceuticals, Inc.Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070202054 *19 Dic 200630 Ago 2007Pipkin James DInhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
US20070249572 *20 Dic 200625 Oct 2007Verus Pharmaceuticals, Inc.Systems and methods for the delivery of corticosteroids
US20080076997 *31 Ago 200727 Mar 2008Abbott Diabetes Care, Inc.Analyte monitoring device and methods of use
US20080107741 *30 Oct 20078 May 2008Elan Pharma International Ltd.Nanoparticulate compositions of angiogenesis inhibitors
US20080279949 *9 May 200813 Nov 2008Elan Pharma International Ltd.Nanoparticulate compositions of angiogenesis inhibitors
US20080287451 *11 Feb 200820 Nov 2008Cook Robert OMethod of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20090104127 *25 Jul 200823 Abr 2009Boehringer Ingelheim KgSuspension aerosol formulations of pharmaceutical products
US20090140851 *23 Jun 20084 Jun 2009Nortel Networks LimitedSystems and methods for facilitating a first response mission at an incident scene using patient monitoring
US20090142407 *4 Jun 20084 Jun 2009Meda Pharama Gmbh & Co. KgSolid peptide preparations for inhalation and their preparation
US20090181100 *26 Ene 200916 Jul 2009Elan Pharma International LtdDry powder aerosols of Nanoparticulate drugs
US20090188491 *16 Ene 200930 Jul 2009Glaxo Group LimitedMedicaments
US20090191134 *12 Jun 200730 Jul 2009Medispray Laboratoriespvt. Ltd.Stable aerosol pharmaceutical formulations
US20100179407 *25 Mar 201015 Jul 2010Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20100312078 *18 Ago 20109 Dic 2010Abbott Diabetes Care Inc.Analyte Monitoring Device and Methods of Use
US20110014134 *27 Sep 201020 Ene 2011Boehringer Ingelheim KgSuspension aerosol formulations of pharmaceutical products
US20120111324 *22 Oct 200810 May 2012Board Of Regents, The University Of Texas SystemDry Powder Drug Delivery Formulations, Methods of Use, and Devices Therefore
USRE446951 May 20127 Ene 2014Dexcom, Inc.Dual electrode system for a continuous analyte sensor
EP0091313A2 *5 Abr 198312 Oct 1983Alcon Laboratories, Inc.Perfluorohydrocarbons as vehicles for administering drugs
EP0091313A3 *5 Abr 198322 May 1985Alcon Laboratories IncPerfluorohydrocarbons as vehicles for administering drugs
EP1066828B24 Dic 19926 Dic 2006Glaxo Group LimitedAerosol compositions
EP1406592A2 *15 Jul 200214 Abr 2004Aeropharm Technology IncorporatedA salt/ion pair medicinal aerosol formulation
EP1406592A4 *15 Jul 200217 Mar 2010Aeropharm Technology IncA salt/ion pair medicinal aerosol formulation
EP1718276A2 *3 Ene 20058 Nov 2006Cydex Inc.Inhalant formulation containing sulfoalkylether cyclodextrin and corticosteroid prepared from a unit dose suspension
EP1718276A4 *3 Ene 200523 Jul 2008Cydex IncInhalant formulation containing sulfoalkylether cyclodextrin and corticosteroid prepared from a unit dose suspension
EP1732512A2 *31 Dic 200420 Dic 2006Cydex Inc.Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1732512A4 *31 Dic 200423 Jul 2008Cydex IncInhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1944016A116 Ago 200216 Jul 2008Baxter International Inc.Propellant-based microparticle formulatons
WO2002094245A1 *21 May 200228 Nov 2002Alexza Molecular Delivery CorporationDelivery of antihistamines through an inhalation route
WO2003015750A1 *16 Ago 200227 Feb 2003Baxter International, Inc.Propellant-based microparticle formulations
Clasificaciones
Clasificación de EE.UU.222/192, 424/114, 514/179, 424/45, 514/653, 514/6.4
Clasificación internacionalA61K31/57, A61K9/00, A61K31/16, A61K31/573
Clasificación cooperativaA61K9/008
Clasificación europeaA61K9/00M20B6